No Data
No Data
OncoCyte Enters Into $10.2 Million Private Placement Agreement
Bio-Rad Upped by Citi to Buy; Charles River, Hologic Downgraded
Bio-Rad Laboratories Analyst Ratings
Citi Upgrades Bio-Rad Laboratories(BIO.US) to Buy Rating, Raises Target Price to $400
Bio-Rad Laboratories Stock: Is BIO Underperforming the Healthcare Sector?
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut
affable Blobfish_403 : The intense struggle between political power and market power in the election, the outcome is uncertain, today's debate is a major highlight.
章允量 :
104476495 : hi